JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hawkinson, J. E.
Right arrow Articles by Upasani, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hawkinson, J. E.
Right arrow Articles by Upasani, R. B.

Vol. 287, Issue 1, 198-207, October 1998

Substituted 3beta -Phenylethynyl Derivatives of 3alpha -Hydroxy-5alpha -pregnan-20-one: Remarkably Potent Neuroactive Steroid Modulators of gamma -Aminobutyric AcidA Receptors

Jon E. Hawkinson, Manuel Acosta-Burruel, Kevin C. Yang, Derk J. Hogenkamp, Jie-Sheng Chen, Nancy C. Lan, John A. Drewe, Edward R. Whittemore, Richard M. Woodward, Richard B. Carter and Ravindra B. Upasani

CoCensys, Inc., Irvine, California

Neuroactive steroids are positive allosteric modulators of gamma -aminobutyric acidA (GABAA) receptor complexes. Synthetic modification generally does not increase neuroactive steroid potency beyond that of the naturally occurring progesterone metabolite, 3alpha -hydroxy-5alpha -pregnan-20-one (3alpha ,5alpha -P). Recently, it has been shown that introduction of appropriately para-substituted phenylethynyl groups at the 3beta -position of 5beta steroids increases receptor potency. The present report presents the synthesis and pharmacological profile of an analogous series of 5alpha steroids. The most striking feature of this series is the further enhancement of in vitro and in vivo potency obtained. In particular, 3beta -(p-acetylphenylethynyl)-3alpha -hydroxy-5alpha -pregnan-20-one (Co 152791) was 11-, 16- and 49-fold more potent than 3alpha ,5alpha -P in modulating the binding of [35S]TBPS, [3H]flunitrazepam and [3H]muscimol, respectively, in rat brain membranes (Co 152791 IC50 or EC50 = 2-7.5 nM). Similarly, Co 152791 was 3- to 20-fold more potent than 3alpha ,5alpha -P as an inhibitor of [35S]TBPS binding in human recombinant receptor combinations containing alpha 1, alpha 2, alpha 3 or alpha 5 and beta 2gamma 2L subunits (Co 152791 IC50 1.4-5.7 nM). Co 152791 displayed low efficacy and 3alpha ,5alpha -P had low potency at alpha 4/6beta 3gamma 2L GABAA receptor complexes. Interestingly, Co 152791 demonstrated remarkable potency as a potentiator of GABA-evoked currents in Xenopus oocytes expressing alpha 1beta 2gamma 2L receptors (EC50 0.87 nM), being 184-fold more potent than 3alpha ,5alpha -P. High in vitro potency was also reflected in enhanced in vivo activity in that Co 152791 exhibited exceptional anticonvulsant potency, protecting mice from pentylenetetrazol-induced seizures at a ~5-fold lower dose than 3alpha ,5alpha -P after i.p. administration (Co 152791 ED50 0.6 mg/kg). Moreover, Co 152791 was orally active (ED50 1.1 mg/kg) and exhibited a therapeutic index of 7 relative to rotorod impairment. The remarkable potency of Co 152791 as a positive allosteric modulator of GABAA receptors may be explained by its interaction with an auxiliary binding pocket in the neuroactive steroid binding site. In addition, modification at the 3beta -position probably hinders metabolism of the 3alpha -hydroxy group contributing to the exceptional anticonvulsant potency of this compound relative to other neuroactive steroids.


0022-3565/98/2871-0198$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
A. J. Smith, B. Oxley, S. Malpas, G. V. Pillai, and P. B. Simpson
Compounds Exhibiting Selective Efficacy for Different {beta} Subunits of Human Recombinant {gamma}-Aminobutyric AcidA Receptors
J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 601 - 609.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. F. Covey, D. Nathan, M. Kalkbrenner, K. R. Nilsson, Y. Hu, C. F. Zorumski, and A. S. Evers
Enantioselectivity of Pregnanolone-Induced gamma -Aminobutyric AcidA Receptor Modulation and Anesthesia
J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 1009 - 1016.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.